CD19 levels and CAR T-cell outcomes in relapsed B-ALL
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how the level of a protein called CD19 on leukemia cells affects outcomes for people who have received CAR T-cell therapy. It aims to better predict who will respond well to this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer that affects white blood cells.
- You must have already received CAR T-cell therapy that targets a protein called CD19 on leukemia cells.
- A bone marrow or blood sample (taken before or after treatment) must be available for testing.
- The sample must have been tested with a standard panel that includes CD19, CD45, CD34, and CD38 markers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving two types of CAR T cells (CD19 and CD22) one after the other works better than giving just one type (CD19) followed by a stem cell transplant for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or not gone away. The goal is to see which approach offers a better chance of long-term remission.
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
This trial tests a new type of immunotherapy called CAR-T cell therapy that targets a protein (CD19) on cancer cells. It is for people with B-cell leukemia or lymphoma that has not responded to standard treatment or has come back, and the goal is to help their immune system fight the cancer.
This trial tests a new type of CAR T cell therapy that targets two proteins (CD19 and CD22) found on leukemia cells. It is for children and young adults whose B-ALL has come back multiple times, or who have not responded to other treatments.
This trial is testing a new CAR-T cell therapy (Senl_B19) for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to treatment. It targets a protein called CD19 on leukemia cells to help your immune system attack the cancer.
This Phase 2 study tests a one-time CAR T-cell treatment aimed at CD19, a target found on many B-cell leukemias and lymphomas. It’s for people whose disease has come back or hasn’t responded to prior treatments, or who can’t have a stem cell transplant.
Hear when a new Relapsed B-ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.